The pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV infected children: a pilot study of Lopimune vs. the branded product (SURF Study)

Trial Profile

The pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV infected children: a pilot study of Lopimune vs. the branded product (SURF Study)

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2010

At a glance

  • Drugs Lopinavir/ritonavir (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Acronyms SURF
  • Most Recent Events

    • 07 Jan 2010 Results published in the Journal of Antimicrobial Chemotherapy.
    • 24 Feb 2009 Actual end date changed from Dec 2008 to Feb 2009 as reported by ClinicalTrials.gov.
    • 24 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top